UK markets open in 3 hours 40 minutes

Futura Medical plc (FAMDF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
0.5000+0.0200 (+4.17%)
At close: 03:42PM EDT

Futura Medical plc

Surrey Technology Centre
40 Occam Road
Guildford GU2 7YG
United Kingdom
44 14 8368 5670

Full-time employees12

Key executives

NameTitlePayExercisedYear born
Mr. James Henry BarderCEO & Executive Director505.08kN/A1959
Ms. Angela HildrethCOO, Finance Director, Company Secretary & Executive Director395.33kN/A1980
Mr. Kenneth William JamesHead of R&D & Executive Director362kN/A1952
Dr. William Duncan PotterChief Scientific Officer & Adviser to the BoardN/A182.85k1948
Graham SmithHead of Alliance Partnerships & SupplyN/AN/AN/A
Kevin LangridgeHead of QualityN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.

Corporate governance

Futura Medical plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.